statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Management expressed positive long-term outlook for the sector and expressed confidence in Syngene's sustained performance on the back of improved fund flows into US biotech in the latter part of the year.

High single digit to low double digits revenue projections for FY 25: Syngene CEO

Syngene's revenue in the fourth quarter of the reported financial year fell seven percent on a year-on-year basis to Rs 916.9 crore, compared to Rs 994 crore in Q4FY23

Syngene International March quarter net profit up 6% to Rs 189 crore, revenue down 8%

CDSL formed robust bullish candlestick pattern on the daily charts with strong volumes. The stock has seen a decisive breakout of consolidation of the recent past sessions and traded well above key moving averages.

Trade Spotlight | Your strategy to deal in Syngene International, IRCTC, CDSL today

Brokerage Goldman Sachs has initiated buy ratings on Syngene International Ltd and Neuland Laboratories Ltd and increased target price to Rs 875 (up 20 percent) and Rs 9100 (up 46 percent), respectively, from current market price. The brokerage house also initiated sell rating on Laurus Labs Ltd with a target price of Rs 350 a share, down 23 percent.

Goldman Sach initiates 'buy' on Syngene, Neuland, adds 'sell' tag to Larus Lab

Experts are hopeful of further uptrend towards 22,700-22,800 in the coming sessions, with support at 22,300-22,200 levels, and the volatility index diving to November 2023 lows

As bulls lead the Street to FY25, experts line up 10 best bets for next 3-4 weeks

Syngene International Ltd. operates as a global discovery, development and manufacturing organization providing integrated scientific services to the pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical industries. It is engaged providing contract research and manufacturing services. The firm’s services include discovery chemistry, discovery biology, safety assessment, large molecule development, chemical development, formulation development, stability studies, polymer research, integrated discovery and development, and clinical development. The company was founded on November 18, 1993 and is headquartered in Bangalore, India.

Volume	6.3M
52-Wk High	860.25
52-Wk Low	631.38

SYNGENE.NSE Syngene International Ltd.

About

Feed

News

Sentiment

Fundamentals